Citrate-mediated disaggregation of rotavirus particles in RotaTeq® vaccine

Antiviral Research

Volumn 69, Issue 2, 2006, Pages 107-115

  Peterson, Susan E ^a   Wang, Shiyi ^a   Ranheim, Todd ^a   Owen, Katey Einterz ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Citrate; Disaggregation; Formulation; RotaTeq ; Rotavirus vaccine

Indexed keywords

BUFFER; CARBOXYLIC ACID; CITRIC ACID; LIVE VACCINE; ROTAVIRUS VACCINE; SUCCINIC ACID;

ANIMAL CELL; ARTICLE; CENTRIFUGATION; DILUTION; DRUG ANALYSIS; GENETIC REASSORTMENT; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; LIGHT SCATTERING; NONHUMAN; PRIORITY JOURNAL; ROTAVIRUS; VACCINE PRODUCTION; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS TITRATION;

ANIMALS; BUFFERS; CATTLE; CERCOPITHECUS AETHIOPS; CHEMISTRY, PHARMACEUTICAL; CITRIC ACID; HUMANS; PLAQUE ASSAY; REASSORTANT VIRUSES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; VERO CELLS; VIRION;

ANIMALIA; ROTAVIRUS;

EID: 31544446069     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.11.001     Document Type: Article

References (28)

1. C.F. Barbas, E. Björling, F. Chiodi, N. Dunlop, D. Cababa, T.M. Jones, S.L. Zebedee, M.A.A. Persson, P.K. Nara, E. Norrby, and D.R. Burton Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro Proc. Natl. Acad. Sci. U.S.A. 89 1992 9339 9343
2. Burke, C.J., Volkin, D.B. (3 August 1999). Rotavirus vaccine formulations. US Patent 5,932,223.
3. M. Ciarlet, and M.K. Estes Rotaviruses: basic biology, epidemiology and methodologies G. Bitton Encyclopedia of Environmental Microbiology 2002 John Wiley and Sons New York 2753 2773
4. H.F. Clark, D.I. Bernstein, P.H. Dennehy, P. Offit, M. Pichichero, J. Treanor, R.L. Ward, D.L. Krah, A. Shaw, M.J. Dallas, D. Laura, J.J. Eiden, N. Ivanoff, K.M. Kaplan, and P. Heaton Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants J. Pediatr. 144 2 2004 184 190
5. H.F. Clark, C.J. Burke, D.B. Volkin, P. Offit, R.L. Ward, J.S. Bresee, P. Dennehy, W.M. Gooch, E. Malacaman, D. Matson, E. Walter, B. Watson, D.L. Krah, M.J. Dallas, F. Schodel, K. Kaplan, and P. Heaton Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation Pediatr. Infect. Dis. J. 22 2003 914 920
6. H.F. Clark, D. Lawley, D. Shrager, D. Jean-Guillaume, P.A. Offit, S.Y. Whang, J.J. Eiden, P.S. Bennett, K.M. Kaplan, and A.R. Shaw Infant immune response to human rotavirus serotyped G1 vaccine candidate reassortant W179-9: different dose response patterns to virus surface proteins VP7 and VP4 Pediatr. Infect. Dis. J. 23 2004 206 211
7. H.F. Clark, P.A. Offit, R.W. Ellis, J.J. Eiden, D. Krah, A.R. Shaw, M. Pichichero, J.J. Treanor, F.E. Borian, L.M. Bell, and S.A. Plotkin The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants J. Infect. Dis. 174 suppl. 1 1996 S73 S80
8. M.K. Estes Rotaviruses and their replication D.M. Knipe P.M. Howley Fields Virology 4th ed. 2001 Lipinsott Williams and Wilkins Philadelphia 1747 1785
9. R. Gajardo, P. Vende, D. Poncet, and J. Cohen Two proline residues are essential in the calcium-binding activity of rotavirus VP7 outer capsid protein J. Virol. 71 1997 2211 2216
10. P. Gómez-Puertas, and J.M. Escribano Blocking antibodies inhibit complete African swine fever virus neutralization Virus Res. 49 1997 115 122
11. Y. Hoshino, R.W. Jones, and A.Z. Kapikian Characterization of neutralization specificities of outer capsid spike protein VP4 of selected murine, lapine, and human rotavirus strains Virology 299 2002 64 71
12. R. Itzler, D. Matson, T. Vesikari, M. Coia, and J. Cook The Effectiveness of a pentavalent (human-bovine) reassortant rotavirus vaccine (PRV) to reduce hospitalizations and emergency department (ED) visits for rotavirus gastroenteritis Pediatric Academic Societies 2005 Annual Meeting Washington, DC, 14-17 May 2005
13. P.A. Offit, H.F. Clark, and R.L. Ward Current state of development of human rotavirus vaccines U. Desselberger J.J. Gray Viral gastroenteritis 2003 Elsevier Science B.V. Amsterdam, Holland 345 356
14. U. Parashar, E. Hummelman, J.S. Bresee, M.A. Miller, and R.I. Glass Global illness and deaths caused by rotavirus disease in children Emerg. Infect. Dis. 9 2003 565 572
15. J.T. Patton, V. Chizhikov, Z. Taraporewala, and D. Chen Gray James Desselberger Ulrich Virus replication, in Rotaviruses: Methods and Protocols 2000 Humana Press Totowa 33 66
16. Ranheim, T., Mathis, P.K., Joelsson, D.B., Smith, M.E., Campbell, K.M., Lucas, G., Barmat, S., Melissen, E., Benz, R., Lewis, J.A., Chen, J., Schofield, T., Sitrin, R.D., Hennessey, J.P., in press. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq®). J. Virol. Meth.
17. M.C. Rex D.C. Dawson W.E. Elliott K.M. Jones Data for Biochemical Research 3rd ed. 2002 Oxford University Press New York
18. M.C. Ruiz, A. Charpilienne, F. Liprandi, R. Gajardo, F. Michelangeli, and J. Cohen The concentration of Ca2+ that solubilizes outer capsid proteins from rotavirus particles is dependent on the strain J. Virol. 70 1996 4877 4883
19. P. Sithisarn, L. Suksanpaisan, C. Thepparit, and D.R. Smith Behavior of dengue virus in solution J. Med. Virol. 71 2003 532 539
20. T.J. Smith, N.H. Olson, R.H. Cheng, H. Liu, E.S. Chase, W.M. Lee, D.M. Leippe, A.G. Mosser, R.R. Rueckert, and T.S. Baker Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody J. Virol. 67 3 1993 1148 1158
21. H.J. Streckert, H. Brüssow, and H. Werchau A synthetic peptide corresponding to the cleavage region of VP3 from rotavirus SA11 induces neutralizing antibodies J. Virol. 62 1988 4265 4269
22. T. Vesikari, H.F. Clark, P. Offit, F. Schödel, and M.J. Dallas The effect of dose and composition of a pentavalent reassortant rotavirus vaccine (RotaTeq™) upon efficacy and immunogenicity in healthy infants Proceedings of the 40th Annual Meeting of the Infectious Diseases Society of America Chicago, IL, 26 October 2002
23. T. Vesikari, D. Matson, P. Van Damme, J. Heyse, and M. Dallas Incidence of intussusception with the pentavalent (human-bovine) reassortant rotavirus vaccine (PRV) is similar to placebo Proceedings of the 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases Valecenia, Spain, 18-20 May 2005
24. T. Vesikari, D. Matson, P. Dennehy, M. Santosham, and Z. Rodriguez Protection against rotavirus gastroenteritis of multiple serotypes by a pentavalent (human-bovine) reassortant rotavirus vaccine (PRV) Proceedings of the 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases Valecenia, Spain, 18-20 May 2005
25. F. Wang, A. Puddy, B. Mathis, A. Montalvo, A. Louis, J. McMackin, J. Xu, Y. Zhang, C. Tan, T. Schofield, J. Wolf, and J. Lewis Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency Vaccine 23 36 2005 4500 4508
26. M. Yeager, K.A. Dryden, N.H. Olson, H.B. Greenberg, and T.S. Baker Three-dimensional structure of rhesus rotavirus by cryoelectron microscopy and image reconstruction J. Cell Biol. 110 6 1990 2133 2144
27. R. Yolken, S. Arango-Jaramillo, J. Eiden, and S. Vonderfecht Lack of genomic reassortment following infection of infant rats with Group A and Group B rotaviruses J. Infect. Dis. 158 1988 1120 1123
28. W. Yuan, and C.R. Parrish Comparison of two single-chain antibodies that neutralize canine parvovirus: analysis of an antibody-combining site and mechanisms of neutralization Virology 269 2000 471 480